DiaDexus, Inc. announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,052,862, covering methods of diagnosing a patient's susceptibility for developing an atherosclerotic disease, including myocardial infarction and stroke, by analyzing a sample of a patient's blood for the presence and activity of Lipoprotein Associated Phospholipase A2 (Lp-PLA2) enzymatic activity to determine a patient's susceptibility to developing atherosclerotic disease, including stroke and myocardial infarction. Lp-PLA2, an enzyme associated with atherosclerotic plaque, was discovered by scientists at GlaxoSmithKline (GSK). This patent is one of several GSK patents to which diaDexus has an exclusive commercial diagnostic license.
Yahoo News